Bio & Pharma
HLB Therapeutics signs contract for COVID vaccine distribution rights
The company will be responsible for vaccine distribution next year in South Korea
By Dec 20, 2022 (Gmt+09:00)
1
Min read
Most Read
S.Korea's LS Materials set to boost earnings ahead of IPO process
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Galaxy Ring, new foldables set to steal the show at Samsung Unpacked Paris
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
POSCO gears up for carbon-free steelmaking with hydrogen
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
SK Inc. in talks to sell Pharmteco’s US CDMO plant to Novo Nordisk
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
South Korea sets sights on fostering EDA tech to win HBM chip war
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
![Moderna vaccine at Incheon Int'l Airport (Courtesy of Yonhap)](https://www.kedglobal.com/data/ked/image/2022/12/20/ked202212200015.700x.0.jpg)
South Korea's pharmaceutical firm HLB Therapeutics Co. said on Monday that it has signed an agreement with the Korea Disease Control and Prevention Agency after being selected as a contractor to build and operate a storage and distribution system for the COVID-19 vaccine next year.
The estimated project volume registered on the Public Procurement Service’s KONEPS Market was 32 billion won($24.6 million), but HLB Therapeutics won the contract by under-bidding at 22.4 billion won, 9.6 billion won less than that projected amount. Meanwhile, GC Biopharma(Green Cross Corp.), which was a contractor this year, bid 32 billion won. The confirmed contract amount is 20.4 billion won except for the value-added tax.
The company explained that it has accumulated experience since last year by taking part in the distribution of the COVID-19 vaccine as a partner to SK Bioscience.
"We will do our best to achieve sales of more than 100 billion won within two years from now based on the technology and know-how of running the nationwide cold chain business for many years," said Lee Pil-hyung, executive director of HLB Therapeutics' Cold Chain Business Headquarters.
Write to Jeong Min Nam at peux@hankyung.com
More to Read
-
COVID-19SK Bioscience seeks WHO nod for prompt COVID vaccine sale
Sep 08, 2022 (Gmt+09:00)
1 Min read -
Bio & PharmaSK Bioscience wins marketing license for Korea's first COVID-19 vaccine
Jun 29, 2022 (Gmt+09:00)
2 Min read -
Bio & PharmaKorean drugmakers close to commercializing COVID-19 vaccine, pill
Apr 25, 2022 (Gmt+09:00)
2 Min read
Comment 0
LOG IN